News – Page 2 – Alectos Therapeutics

Alectos Therapeutics Announces FDA Orphan Drug Designation for MK-8719: An Investigational Small-molecule OGA Inhibitor for Treatment of Progressive Supranuclear Palsy

Advances Novel Tau-directed Strategy for Treating Neurodegenerative Disease Phase 1 [...]

Apr 18, 2016 – Alectos Therapeutics partner Merck, known as MSD [...]

Administrator2016-04-18T22:31:51-07:00April 18, 2016|Categories: News|Tags: Alzheimer's, Merck, MK-6240, MK-8719, OGA, Tau, Tau PET|

Feb 11, 2016 – Alectos today announced its support for [...]

Administrator2016-02-11T23:52:49-08:00February 11, 2016|Categories: News|Tags: Bennet, GCase, NSERC, Parkinson's, SFU|

Feb 17, 2015 – Alectos today announced its support as [...]

Administrator2015-02-17T23:07:30-08:00February 17, 2015|Categories: News|Tags: GlycoNet, NSERC, SFU|

Vancouver, British Columbia (December 12, 2014) – Alectos Therapeutics Inc. [...]

Administrator2014-12-12T23:43:32-08:00December 12, 2014|Categories: News|Tags: Alzheimer's, Merck, Milestone, OGA|

Oct 26, 2014 – Alectos today announced publication of preclinical [...]

Administrator2014-10-26T19:34:28-07:00October 26, 2014|Categories: News|Tags: Alzheimer's, Amyloid, NFTs, OGA, SFU, TAPP, Tau, Thiamet-G|

Oct 6, 2014 – Alectos today announced its support for [...]

Administrator2014-10-06T23:16:49-07:00October 6, 2014|Categories: News|Tags: Boulanger, GCase, NSERC, Parkinson's, UVic|

May 22, 2014 – Alectos today announced publication of preclinical [...]

Administrator2014-05-22T21:48:03-07:00May 22, 2014|Categories: News|Tags: Ac-5SGlcNAc, Cancer metabolism, OGT, SFU|

Vancouver, British Columbia (November 16, 2012) – Alectos Therapeutics Inc. [...]

Administrator2012-11-16T22:37:20-08:00November 16, 2012|Categories: News|Tags: Alzheimer's, Merck, Milestone, OGA|

July 16, 2012 – Alectos today announced its support for [...]

Administrator2012-07-16T23:18:12-07:00July 16, 2012|Categories: News|Tags: Cancer metabolism, NSERC, Pinto, SFU|